Novo NVO and Pfizer PFE are both pharmaceutical giants based in Denmark and the United States, respectively, with broad portfolios spanning major therapeutic areas. Novo is widely recognized for its leadership in diabetes and obesity, with its semaglutide franchise marketed under the Ozempic and Rybelsus brands for type II diabetes (T2D) and Wegovy for chronic weight management. The company is also expanding its obesity offering with oral formulations, seeking to broaden its reach in the fast-growing weight-loss market. Pfizer, meanwhile, has traditionally maintained significant strength across oncology, vaccines, inflammation and immunology, rare diseases and other therapeutic areas.
Wir zeigen den wichtigsten Punkt oeffentlich. Erstellen Sie ein kostenloses Konto, um den vollstaendigen Artikel zu lesen, ihn zu speichern, zu diskutieren und mit Markt- und OSINT-Kontext zu verbinden.